Page 12 - Graphite Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Compugen (NASDAQ:CGEN – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations. Profitability This table compares Compugen and Graphite Bio’s net margins, […]

In this article, we will take a look at the 11 most promising gene editing stocks according to analysts.

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 EPS estimates for shares of Graphite Bio in a research report issued on Monday, March 20th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($0.13) for the quarter, up from […]

Jonathan MacQuitty talks about cell and gene therapy shortcomings and the challenges for private companies at different funding stages in 2023.

BioPharma